NCT06634160Active, not recruiting
Assessment of the Prevalence of Steatotic Liver Disease Associated With Metabolic Dysfunction in Patients With Heterozygous Familial Hypercholesterolemia
Assessment of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) Prevalence in Patients With Heterozygous Familial Hypercholesterolemia (HeFH): the STEATO-FH Study
Source: ClinicalTrials.gov · Last updated 29 Oct 2026
Brief summary (registry, in English)
The main goal of the STEATO-FH study is to determine the prevalence of liver steatosis within the Heterozygous Familial Hypercholesterolemia patient population.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 4 Oct 2024
- Start date
- 30 Jan 2025
- Primary completion date
- 22 Oct 2026
- Lead sponsor
- Nantes University Hospital
- NCT number
- NCT06634160
What you commit to
- Study type: Observational
- Planned participants: 200
- From 30 Jan 2025 to the primary completion date, 22 Oct 2026
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current treatment with a drug likely to cause hepatic steatosis, including amiodarone, carbamazepine, tamoxifen, valproate, clozapine, anti-retrovirals
- Current oral corticosteroid therapy unless dose has been stable for ≥ 3 months
Other illness
- Active viral hepatitis
- Other genetic or autoimmune hepatitis
Other
- Protected patients: minors, adults under guardianship, curatorship and/or safeguard of justice
- Pregnant or breast-feeding
- Hemochromatosis
- Current pathological alcohol consumption (≥ 60 g/day in men and ≥ 50 g/day in women)
Who the study is looking for
- Patient aged 35 or over
- Consultation at Nantes, Rennes or Angers University Hospital during the inclusion period
- With a diagnosis of familial hypercholesterolemia defined by the presence of a genetic variant, ACMG classes 4 \& 5 on LDLR, APOB or PCSK9
- Patient not objecting to inclusion in study (no written objection)
Age in the registry: 35 years to - · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU Angers Coordinator of this site? Confirm its status | Angers | France | Unknown status |
| CHU Nantes Coordinator of this site? Confirm its status | Nantes | France | Unknown status |
| Rennes University Hospital Coordinator of this site? Confirm its status | Rennes | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.